Edition:
India

Fate Therapeutics Says FDA Clears IND Application For Cell Therapy Derived From An Engineered Pluripotent Stem Cell


Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR WORLD’S FIRST CELL THERAPY DERIVED FROM AN ENGINEERED PLURIPOTENT STEM CELL.FATE THERAPEUTICS INC - FT516 OFF--SHELF NK CELL CANCER IMMUNOTHERAPY CLEARED FOR CLINICAL INVESTIGATION BY FDA.FATE THERAPEUTICS INC - FDA HAS ALLOWED ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR FT516.FATE THERAPEUTICS INC - COMPANY INTENDS TO INITIATE CLINICAL TESTING OF FT516 IN PATIENTS WITH CERTAIN RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES. 

Company Quote

22.46
 --
16 Jul 2019